We Can Diagnose AKI "Early"
- SourceAvailable from: Talat Alp Ikizler[Show abstract] [Hide abstract]
ABSTRACT: Biomarker studies for early detection of acute kidney injury (AKI) have been limited by nonselective testing and uncertainties in using small changes in serum creatinine as a reference standard. Here we examine the ability of urine L-type fatty acid-binding protein (L-FABP), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), and kidney injury molecule-1 (KIM-1) to predict injury progression, dialysis, or death within 7 days in critically ill adults with early AKI. Of 152 patients with known baseline creatinine examined, 36 experienced the composite outcome. Urine L-FABP demonstrated an area under the receiver-operating characteristic curve (AUC-ROC) of 0.79 (95% confidence interval 0.70-0.86), which improved to 0.82 (95% confidence interval 0.75-0.90) when added to the clinical model (AUC-ROC of 0.74). Urine NGAL, IL-18, and KIM-1 had AUC-ROCs of 0.65, 0.64, and 0.62, respectively, but did not significantly improve discrimination of the clinical model. The category-free net reclassification index improved with urine L-FABP (total net reclassification index for nonevents 31.0%) and urine NGAL (total net reclassification index for events 33.3%). However, only urine L-FABP significantly improved the integrated discrimination index. Thus, modest early changes in serum creatinine can help target biomarker measurement for determining prognosis with urine L-FABP, providing independent and additive prognostic information when combined with clinical predictors.Kidney International advance online publication, 17 September 2014; doi:10.1038/ki.2014.301.Kidney International 09/2014; 87(3). DOI:10.1038/ki.2014.301 · 8.52 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Hospitalized children are experiencing acute kidney injury (AKI) with increasing frequency and are especially vulnerable to its long-term complications. Attempts to leverage novel biomarkers to improve phenotyping of this disease are limited by untargeted testing within broadly selected populations. Here, we review efforts by Basu et al. to use readily available clinical information to identify critically ill children at higher risk for developing severe AKI, who may benefit from novel diagnostic and prognostic information.Kidney International 03/2014; 85(3):494-5. DOI:10.1038/ki.2013.389 · 8.52 Impact Factor